AN OPEN-LABEL, EXPLORATORY STUDY TO ESTABLISH THE EFFICACY AND SAFETY OF 1-YEAR CANAKINUMAB TREATMENT IN BEHCET'S DISEASE PATIENTS WITH NEUROLOGIC OR VASCULAR INVOLVEMENT

被引：0
|
作者：
Gul, A. [1 ]
Kurtuncu, M. [1 ]
Erdugan, M. [1 ]
Oguz, E. [1 ]
Gunduz, T. [1 ]
Demir, G. Akman [1 ]
Sevgi, S. [2 ]
Turgay, S. [2 ]
Acar, E. [2 ]
机构：
[1] Istanbul Fac Med, Istanbul, Turkey
[2] Novartis Turkey, Istanbul, Turkey
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.4247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0480
引用
收藏
页码：1533 / 1534
页数：2
相关论文
共 50 条
  • [1] CANAKINUMAB TREATMENT IN BEHCET'S DISEASE PATIENTS WITH NEUROLOGIC OR VASCULAR INVOLVEMENT
    Gul, A.
    Demir, G. A.
    Kurtuncu, M.
    Erer, B.
    Sevgi, S.
    Turgay, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : S184 - S185
  • [2] Canakinumab for Behcet's Disease Resistant to Standard Treatment (CanBeDisT) - an open-label single center pilot study
    Koetter, I.
    Deuter, C.
    Henes, J.
    Xenitidis, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S187 - S187
  • [3] A 16-week open-label study on the efficacy and safety of canakinumab treatment in urticarial vasculitis
    Krause, K.
    Mahamed, A.
    Maurer, M.
    EXPERIMENTAL DERMATOLOGY, 2013, 22 (03) : E12 - E12
  • [4] A 1-Year, Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder
    Robinson, Donald S.
    Kajdasz, Daniel K.
    Gallipoli, Susan
    Whalen, Heidi
    Wamil, Art
    Reed, Carol R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (05) : 643 - 646
  • [5] Efficacy and safety of α-dihydroergocryptine in the treatment of early and advanced Parkinson's disease:: An open-label study
    Peng, R
    Zhou, D
    Lai, XH
    Yuan, GG
    MOVEMENT DISORDERS, 2004, 19 : S228 - S228
  • [6] Adalimumab in patients with Crohn's disease -: safety and efficacy in an open-label single centre study
    Seiderer, J.
    Brand, S.
    Dambacher, J.
    Pfennig, S.
    Juergens, M.
    Goeke, B.
    Ochsenkuehn, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (07) : 787 - 796
  • [7] Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study
    Grayson, Peter C.
    Yazici, Yusuf
    Merideth, Melissa
    Sen, H. Nida
    Davis, Michael
    Novakovich, Elaine
    Joyal, Elizabeth
    Goldbach-Mansky, Raphaela
    Sibley, Cailin H.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [8] A PROSPECTIVE, 1-YEAR, OPEN-LABEL, FLEXIBLE DOSE STUDY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA: SAFETY, TOLERABILITY, AND EFFECTIVENESS
    Hiroki, Ogo
    Masakuni, M.
    Masaaki, O.
    Cucchiaro, J.
    Siu, C.
    Loebel, A.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 305 - 306
  • [9] Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study
    Hibi, Toshifumi
    Hirohata, Shunsei
    Kikuchi, Hirotoshi
    Tateishi, Ukihide
    Sato, Noriko
    Ozaki, Kunihiko
    Kondo, Kazuoki
    Ishigatsubo, Yoshiaki
    MEDICINE, 2016, 95 (24)
  • [10] Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
    Naing, Aung
    Mahipal, Amit
    Javle, Milind
    Wang, Judy
    Bauer, Todd M.
    Bajor, David L.
    Elias, Anthony D.
    Shields, Anthony
    Davis, Elizabeth
    Chawla, Sant
    Safran, Howard
    Powderly, John D.
    D'Amato, Gina
    Meyer, Christian F.
    Tang, Xiongwen
    Yao, Sheng
    Keegan, Patricia
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (01) : 71 - 81
12345